Patent US4439413A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4439413A Expired / Lapsed US ⏱️ 0.0 years remaining

Radioactive diagnostic agent for bone scanning and non-radioactive carrier therefor

Assignee: NILHON MEDI-PHYSICS Co Ltd
•
Filing: 1981-09-11
•
Granted: 1984-03-27
•
Expires: 2001-09-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A radioactive diagnostic agent for bone scanning, which comprises 99mTc and a non-radioactive carrier comprising (A) at least one chosen from methanehydroxydiphosphonic acid and their salts and (B) at least one reducing agent for pertechnetates in a weight ratio of about 1:1 to 7:1 and prevents the accumulation of radioactivity in liver so that definite diagnosis can be assured.

Inventors

  • 👤 Miki Hayashi
  • 👤 Keietsu Takahashi
  • 👤 Masaaki Hazue

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 09:25
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K2123/00

Claims Analysis

Total Claims: 19
Claim 1
Independent Claim 34 words
A non-radioactive carrier, which comprises (A) methanehydroxydiphosphonic acid or a pharmaceutically acceptable water soluble salt thereof and (B) at least one reducing agent for pertechnetates in a weight ratio of about 1:1 to 7:1.
Claim 2
Dependent Claim 34 words
A non-radioactive carrier, which comprises (A) methanehydroxydiphosphonic acid or a pharmaceutically acceptable water soluble salt thereof and (B) at least one reducing agent for pertechnetates in a weight ratio of about 1:1 to 7:1.
Claim 3
Dependent Claim 22 words
The carrier according to claim 1, wherein the weight ratio of the components (A) and (B) is from about 1:1 to 3:1.
Claim 4
Dependent Claim 15 words
The carrier according to claim 1, wherein the components (A) and (B) are both water-soluble.
Claim 5
Dependent Claim 14 words
The carrier according to claim 1, wherein the component (B) is a stannous salt.
Claim 6
Dependent Claim 18 words
The carrier according to claim 1, wherein the components (A) and (B) are dissolved in an aqueous medium.
Claim 7
Dependent Claim 13 words
The carrier according to claim 1, which is in a lyopholized powder state.
Claim 8
Dependent Claim 15 words
The carrier according to claim 1, which further comprises (C) a pharmaceutically acceptable reductive stabilizer.
Claim 9
Dependent Claim 27 words
The carrier according to claim 7, wherein the component (C) is the one chosen from ascorbic acid, erythorbic acid and gentisic acid, and their salts or esters.
Claim 10
Dependent Claim 22 words
The carrier according to claim 7, wherein the weight proportion of the components (A) and (C) is from about 1:1 to 20:1.
Claim 11
Dependent Claim 46 words
A radioactive diagnostic agent for bone scanning which comprises 99m Tc and a non-radioactive carrier which comprises (A) methanehydroxydiphosphonic acid or a pharmaceutically acceptable water soluble salt thereof and (B) at least one reducing agent for pertechnetates in a weight ratio of about 1:1 to 7:1.
Claim 12
Dependent Claim 46 words
A radioactive diagnostic agent for bone scanning which comprises 99m Tc and a non-radioactive carrier which comprises (A) methanehydroxydiphosphonic acid or a pharmaceutically acceptable water soluble salt thereof and (B) at least one reducing agent for pertechnetates in a weight ratio of about 1:1 to 7:1.
Claim 13
Dependent Claim 51 words
A radioactive diagnostic agent for bone scanning which comprises 99m Tc in the form of pertechnetate and a non-radioactive carrier which comprises (A) methanehydroxydiphosphonic acid or a pharmaceutically acceptable water soluble salt thereof and (B) at least one reducing agent for pertechnetates in a weight ratio of about 1:1 to 7:1.
Claim 14
Dependent Claim 51 words
A radioactive diagnostic agent for bone scanning which comprises 99m Tc in the form of pertechnetate and a non-radioactive carrier which comprises (A) methanehydroxydiphosphonic acid or a pharmaceutically acceptable water soluble salt thereof and (B) at least one reducing agent for pertechnetates in a weight ratio of about 1:1 to 7:1.
Claim 15
Dependent Claim 24 words
The diagnostic agent as in claim 10 or 11 wherein the weight ratio of components (A) and (B) is from about 1:1 to 3:1.
Claim 16
Dependent Claim 16 words
The diagnostic agent as in claim 10 or 11 wherein component (B) is a stannous salt.
Claim 17
Dependent Claim 21 words
The diagnostic agent as in claim 10 or 13 wherein the components (A) and (B) are dissolved in an aqueous medium.
Claim 18
Dependent Claim 16 words
The diagnostic agent as in claim 10 or 13 which is in a lyophilized powder form.
Claim 19
Dependent Claim 18 words
The diagnostic agent as in claim 10 or 11 which further comprises (C) a pharmaceutically acceptable reductive stabilizer.

References Cited (Backward Citations)

US4234562A Cited
US4233284A Cited
US4229427A Cited
US4232000A Cited
US4247534A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-03-27 1987-09-26 1988-03-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-03-27 1991-09-26 1992-03-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-03-27 1995-09-26 1996-03-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag